Tarsus Pharmaceuticals plans $100 million public offering of common stock, focused on eye care

From GlobeNewswire: 2025-03-12 16:12:00

Tarsus Pharmaceuticals, Inc. has announced a public offering of $100.0 million of its common stock, with the option for underwriters to purchase an additional $15.0 million. The offering is subject to market conditions and may not be completed. Goldman Sachs & Co. LLC, BofA Securities, Barclays, and Oppenheimer & Co. are acting as joint book-running managers. The company is focused on revolutionizing treatment for patients, particularly in eye care and infectious disease prevention. The offering will be made through a prospectus supplement filed with the SEC. Investors should consider the risks and uncertainties outlined in Tarsus’ filings with the SEC.



Read more at GlobeNewswire: Tarsus Announces Proposed $100.0 Million Public Offering